Wealthcare Advisory Partners LLC decreased its position in Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 16.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,849 shares of the company’s stock after selling 1,336 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Moderna were worth $1,180,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in MRNA. Fieldpoint Private Securities LLC increased its holdings in shares of Moderna by 103.8% in the 1st quarter. Fieldpoint Private Securities LLC now owns 214 shares of the company’s stock worth $37,000 after purchasing an additional 109 shares in the last quarter. HM Payson & Co. boosted its position in shares of Moderna by 107.6% during the fourth quarter. HM Payson & Co. now owns 301 shares of the company’s stock valued at $76,000 after buying an additional 156 shares during the last quarter. Victory Capital Management Inc. increased its holdings in Moderna by 9.3% in the 4th quarter. Victory Capital Management Inc. now owns 256,403 shares of the company’s stock worth $65,121,000 after buying an additional 21,738 shares in the last quarter. American National Bank raised its position in Moderna by 519.0% in the 4th quarter. American National Bank now owns 130 shares of the company’s stock worth $33,000 after buying an additional 109 shares during the last quarter. Finally, Horizon Investments LLC lifted its stake in Moderna by 35.9% during the 4th quarter. Horizon Investments LLC now owns 7,544 shares of the company’s stock valued at $1,916,000 after acquiring an additional 1,992 shares during the period. 61.20% of the stock is currently owned by institutional investors.
MRNA has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft dropped their price target on Moderna from $175.00 to $155.00 and set a “hold” rating on the stock in a research note on Monday, March 7th. Piper Sandler cut their target price on shares of Moderna from $348.00 to $214.00 and set an “overweight” rating for the company in a research report on Tuesday, May 17th. SVB Leerink decreased their price target on shares of Moderna from $80.00 to $70.00 and set an “underperform” rating on the stock in a research report on Tuesday, June 7th. Finally, Morgan Stanley boosted their price objective on shares of Moderna from $205.00 to $217.00 and gave the company an “equal weight” rating in a research report on Tuesday, April 12th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $228.00.
Moderna (NASDAQ:MRNA – Get Rating) last announced its earnings results on Wednesday, May 4th. The company reported $8.58 EPS for the quarter, topping analysts’ consensus estimates of $5.18 by $3.40. The firm had revenue of $6.07 billion during the quarter, compared to analysts’ expectations of $4.43 billion. Moderna had a return on equity of 121.86% and a net margin of 64.77%. The company’s quarterly revenue was up 213.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.84 EPS. As a group, research analysts forecast that Moderna, Inc. will post 27.27 earnings per share for the current year.
In other Moderna news, President Stephen Hoge sold 20,000 shares of Moderna stock in a transaction on Monday, April 4th. The stock was sold at an average price of $177.27, for a total transaction of $3,545,400.00. Following the completion of the sale, the president now directly owns 1,622,532 shares of the company’s stock, valued at approximately $287,626,247.64. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Juan Andres sold 2,000 shares of the stock in a transaction on Wednesday, March 30th. The stock was sold at an average price of $182.79, for a total value of $365,580.00. The disclosure for this sale can be found here. Insiders have sold a total of 382,029 shares of company stock valued at $54,197,245 over the last three months. 17.30% of the stock is owned by corporate insiders.
Moderna Profile (Get Rating)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- How to Screen for Cash Value Stocks in a Bear Market
- Zoom Stock is Not All Gloom and Doom
- MarketBeat: Week in Review 6/20 – 6/24
- GMS Inc. Posts Strong Results As The Housing Backlog Drives Earnings
- Blackberry Continues To Struggle As Management Remains Asleep At The Wheel
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.